External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home EULAR 2024
Roche and Genentech at

EULAR 2024

June 12 - June 15
Vienna, Austria
eular.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon

Sign up or login to unlock the full suite of MEDICALLY features
Jun 14 / Roche and Genentech
Evaluating the concordance between SRI-4 and BICLA in the EXPLORER and ATHOS trials in active systemic lupus erythematosus
This post hoc analysis of 2 systemic lupus erythematosus randomized controlled trials (EXPLORER [NCT00137969] and ATHOS [NCT02908100]) examined concordance in British Isles Lupus Assessment Group (BILAG)–based Composite Lupus Assessment (BICLA) and Systemic Lupus Erythematosus Responder Index 4 (SRI-4) outcome measures among participants receiving placebo and standard of care (SOC) and explored reasons for BICLA and SRI-4 discordance.
Immunology Systemic Lupus Erythematosus EULAR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jun 12 / Roche and Genentech
Obinutuzumab benefits patients with active lupus nephritis irrespective of baseline proteinuria severity: a post hoc analysis of the Phase II NOBILITY trial
This post hoc analysis assessed the achievement of complete renal response (CRR) in participants with lupus nephritis from the Phase 2 NOBILITY trial (NCT02550652) using primary endpoint definitions from the ongoing Phase 3 REGENCY (NCT04221477) and completed BLISS-LN trials. In addition, this analysis evaluated the effect of proteinuria at baseline on achieving the REGENCY CRR.
Nephrology Lupus nephritis EULAR-2024

Sign up or login to unlock the full suite of MEDICALLY features
Jun 12 / Roche and Genentech
Longitudinal Assessment of Biomarkers in NOBILITY, a Randomized, Phase II Clinical Trial of Obinutuzumab for Treatment of Proliferative Lupus Nephritis
This post hoc analysis evaluated changes in peripheral B cells, B-cell subsets and serum biomarkers of disease activity (autoantibodies, complement C3/C4) in patients with lupus nephritis treated with obinutuzumab in the Phase II, randomized, double-blind, placebo-controlled NOBILITY trial (NCT02550652).
Nephrology Lupus nephritis EULAR-2024
01:30 PM
Duration 1hr Vienna, Austria
Obinutuzumab benefits patients with active lupus nephritis irrespective of baseline proteinuria severity: a post hoc analysis of the Phase II NOBILITY trial
Furie R, Terres J, Martins E, Hassan I, Schindler T, Garg J, Pendergraft W, Malvar A, Rovin B
Nephrology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
02:30 PM
Duration 10mins Session Room C8
Longitudinal Assessment of Biomarkers in NOBILITY, a Randomized, Phase II Clinical Trial of Obinutuzumab for Treatment of Proliferative Lupus Nephritis
Edward M. Vital
Nephrology | Lupus nephritis

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 AM
Duration 90mins Vienna, Austria
Evaluating the concordance between SRI-4 and BICLA in the EXPLORER and ATHOS trials in active systemic lupus erythematosus
Askanase A, Vital E, Terres J, Maller J, Meier O, Turchetta A, Mao A, Dall'Era M
Immunology | Systemic Lupus Erythematosus

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.